Colistin; Pseudomonas aeruginosa; Acinetobacter baumannii Summary Objective: To determine the efficacy and safety of colistin (colistimethate sodium) produced by a local pharmaceutical company in Thailand for the treatment of infections caused by multidrugresistant (MDR) Pseudomonas aeruginosa and Acinetobacter baumannii. Methods: Patients hospitalized at Siriraj Hospital between January 2005 and April 2006, who had infections caused by MDR P. aeruginosa or A. baumannii, were enrolled in the study. Colistin (colistimethate sodium) at a dosage of 5 mg/kg/day was given intravenously in two divided doses. Primary outcomes were the clinical response and 30-day mortality; secondary outcomes were microbiological response and adverse events. Results: Ninety-three patients infected with MDR P. aeruginosa and A. baumannii were enrolled. Seventy-eight patients (71 with A. baumannii and seven with P. aeruginosa) received colistin, whereas 15 patients (12 with A. baumannii and three with P. aeruginosa) received other antibiotics. The mean age, gender, underlying conditions and severity of illness of the patients in both groups were not significantly different. In the colistin group, 63 patients (80.8%) had a favorable clinical response and 94.9% had a microbiological response. The overall mortality of the patients in the colistin group was 46.2% and that in the non-colistin group was 80%. Nephrotoxicity was found in 24 patients (30.8%) in the colistin group and 17 of them had predisposing factors contributing to their renal dysfunction. No neurotoxicity was observed among the 78 patients.
Introduction
Nosocomial infections caused by multidrug-resistant (MDR) organisms are emerging worldwide. [1] [2] [3] The incidence of MDR pathogens, particularly Acinetobacter baumannii and Pseudomonas aeruginosa, in Thailand has dramatically increased. 4 A prospective cohort study of 208 clinical isolates of A. baumannii recovered from the patients in Siriraj Hospital from January to December 2002, revealed that 86 strains (41.3%) were isolated from the infected patients and the remaining 58.7% were colonizers. 5 In this study, 57% of A. baumannii isolates were resistant to all antimicrobial agents available in Thailand including beta-lactams, aminoglycosides and fluoroquinolones, and the overall mortality rate of the patients infected with pandrug-resistant A. baumannii was 79%. 5 The study of 104 clinical isolates of A. baumannii from 100 hospitalized patients at Maharaj Nakorn Chiang Mai hospital, Thailand also observed that 46% of the isolates were pandrug-resistant and the overall mortality was 52%. 6 Over the past few years there have been reports on treating patients infected with MDR A. baumannii and P. aeruginosa with polymyxin B and colistin. [7] [8] [9] They found that polymyxin B and colistin had modest efficacy and were safe. In vitro activity of polymyxin B and colistin against 100 clinical isolates of MDR A. baumannii and 100 isolates of P. aeruginosa collected from the patients hospitalized at Siriraj Hospital from 2002 and 2003, revealed that all isolates were susceptible to polymyxin B and colistin. 10 However polymyxins are not available in Thailand and international pharmaceutical companies do not have a policy to import polymyxins to Thailand. Therefore we asked a local pharmaceutical company to produce colistin and this product has been approved by the Thai Food and Drug Administration since 2004.
The objective of this study was to determine the efficacy and safety of colistin produced by a local pharmaceutical company in Thailand for the treatment of infections caused by MDR P. aeruginosa and A. baumannii.
Methods
The study was approved by the ethics committee on human research of the Faculty of Medicine Siriraj Hospital, and all participating subjects signed the informed consent form. This was a pragmatic clinical trial conducted at Siriraj Hospital, Bangkok, Thailand, between January 2005 and April 2006. The eligible subjects were hospitalized patients over the age of 18 years who were infected with A. baumannii or P. aeruginosa resistant to beta-lactams, fluoroquinolones and aminoglycosides. We excluded patients with infections caused by A. baumannii or P. aeruginosa with other bacteria from our study because we felt that it was difficult to determine the efficacy of colistin for treatment of infections caused by MDR A. baumannii or P. aeruginosa. Colistin was offered to all such patients and if the patients and their responsible physicians agreed to have colistin treatment, the patients received intravenous colistin (colistimethate sodium) of 5 mg/kg/day in two divided doses. The dosage of colistin was adjusted according to the patients' renal function. 11 If the patients or their responsible physicians did not wish to join the study, they received other antibiotics according to their physicians' decisions and these patients were defined as the 'non-colistin group'.
All isolates of A. baumannii and P. aeruginosa from the eligible patients were tested for colistin susceptibility by Etest according to the manufacturer's guidelines (AB Biodisk, Sweden). A suspension of each isolate in Mueller-Hinton broth (BBL-Becton Dickinson, USA), adjusted to the density of a 0.5 McFarland standard, was swabbed in three directions to ensure uniform growth onto Mueller-Hinton agar (BBLBecton Dickinson, USA) plates. Once the agar surface was completely dry, an E-test colistin strip (ranging from 0.06 to 1024 mg/ml) was applied to each plate and the plates were incubated at 35 8C for 16-20 hours. The minimum inhibitory concentration (MIC) was read where inhibition of growth intersected the E-test strip. Quality control strains of Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853 were used with the reference MIC range of 0.125-0.5 and 0.5-2 mg/l, respectively. The susceptible isolate was defined as having a MIC of 2 mg/l. Quantitative colistin serum level was determined by microbiological assay. 12 The primary outcomes were the clinical response and 30-day mortality. A good clinical response referred to a combination of clinical cure and clinical improvement. Clinical cure was defined as a disappearance of symptoms and signs of infection and clinical improvement was defined as a partial resolution of the symptoms and signs of infection. The secondary outcomes were microbiological response and adverse effects. Successful microbiological response was defined as an eradication of the causative organisms at the end of treatment. Nephrotoxicity was defined as an increase in serum creatinine of at least two-fold of the baseline value or a 30% decrease of creatinine clearance from the baseline value.
Results
Between January 2005 and April 2006, 93 patients met the inclusion criteria. Seventy-eight patients were in the colistin group and 15 patients in the non-colistin group. The baseline characteristics of the patients are shown in Table 1 . The mean age, gender, underlying conditions, and severity of illness of the patients in both groups were not significantly different.
Presenting infections in the colistin group were: pneumonia (54), bacteremia and/or catheter related infection (9), intra-abdominal infection (5), urinary tract infection (4), skin and soft tissue infection (5), and sinusitis (1). In the colistin group, 71 patients (91%) were infected with A. baumannii and Colistin and multidrug-resistant P. aeruginosa and A. baumannii seven (9%) were infected with P. aeruginosa, whereas 12 patients (80%) were infected with A. baumannii and three (20%) were infected with P. aeruginosa in the non-colistin group. In vitro susceptibility tests determined by E-test revealed that all A. baumannii and P. aeruginosa isolates had a MIC of colistin less than 2 mg/l and were considered susceptible to colistin. In the colistin group, 33 patients (42.3%) received colistin alone, whereas 45 patients (57.7%) received colistin with other antibiotics including vancomycin, aminoglycosides, metronidazole or carbapenems. In the non-colistin group, the patients received carbapenems (6), cefoperazone/sulbactam (3), cefoperazone/ sulbactam combined with netilmicin (4), and cefoperazone/ sulbactam combined with carbapenem (2).
The treatment outcomes are shown in Table 2 . Sixty-four patients (82.1%) in the colistin group had a good clinical response. The clinical response in the patients who received colistin alone was 84.8% and in those who received colistin with other antibiotics was 77.8%; only four patients (26.7%) in the non-colistin group responded.
All cause mortality within 30 days was 46.2% in the colistin group and 80% in the non-colistin group ( p = 0.03). The relative risk of death in the colistin group was 0.58 of the non-colistin group with a 95% confidence interval (CI) of 0.41 to 0.82. The difference in mortality was statistically significant and the number needed to treat (NNT) was approximately three, which implies that only three patients infected with MDR A. baumannii or P. aeruginosa needed to be treated with colistin in order to prevent one additional death. The overall mortality rates of the patients infected with A. baumannii and P. aeruginosa in the colistin group were 46.5% and 42.9%, respectively.
A microbiological response was found in 94.9% of the patients in the colistin group and none in the non-colistin group. Nephrotoxicity was observed in 24 patients (30.8%) in the colistin group. The incidence of nephrotoxicity of the patients in the colistin group was significantly less than that in the non-colistin group. Seventeen (70.8%) of 24 patients in the colistin group who developed nephrotoxicity had other predisposing factors contributing to a decline in renal function including nephrotoxic drugs, chronic kidney diseases, and hypovolemia. Nephrotoxic effects were mild and reversible without requiring renal replacement therapy. No neurotoxicity or drug reaction was observed in the patients who received colistin. The average dose of colistin was 179.6 mg/ day, the average duration of colistin treatment was 11.9 days, and the average total dose of colistin was 2.1 g/ patient/course.
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Discussion
This study used colistimethate sodium (also called colistin methanesulfate, pentasodium colistimethane sulfate, or colistin sulfonyl methate), which is less potent and less toxic than colistin sulfate. 13, 14 Colistin has a narrow spectrum of antimicrobial activity and is active against most aerobic Gram-negative bacilli including P. aeruginosa and Acinetobacter spp, even the organisms that are multidrug-resistant. 13 Several reports published during the period 1999 to 2003 revealed that polymyxins were effective and safe for treatment of patients infected with MDR Gram-negative bacteria including A. baumannii and P. aeruginosa. [7] [8] [9] We therefore attempted to study the efficacy and safety of locally produced colistin.
We were unable to do a randomized controlled study to compare colistin with other antibiotics since it would be unethical to provide antibiotics likely to be ineffective to patients, while the antibiotic active against the causative pathogens, colistin, was available. Therefore we had to offer colistin to all patients who had infections caused by A. baumannii or P. aeruginosa resistant to beta-lactams, fluoroquinolones and aminoglycosides. However, the baseline characteristics of the patients including mean age, gender, underlying conditions, severity of illness and the sites of infections of the patients in both groups were comparable.
The results from our study also showed a good clinical outcome and less overall mortality in patients who received colistin for treatment of MDR A. baumannii and P. aeruginosa. A good clinical outcome was found in 82.1% of patients treated with colistin no matter how the patients received it, alone or with other antibiotics. Overall mortality decreased from 79% in a previous study of A. baumannii infections in the same hospital to 46.5% of the patients infected with A. baumannii treated with colistin in this study. 5 The overall mortality in the non-colistin group in this study was still up to 80%. Furthermore, NNT for mortality from our study was only three, indicating that only three patients infected with MDR A. baumannii or P. aeruginosa needed to be treated with colistin in order to prevent one additional death. Moreover the cost of colistin was approximately 10 to 20 times lower than that of other antibiotics used to treat MDR A. baumannii and P. aeruginosa such as carbapenems, cefoperazone/sulbactam, and cephalosporins with or without aminoglycosides.
A microbiological response was observed in 74 patients (94.9%) in the colistin group. Three patients who did not have a microbiological response also had a good clinical outcome. However, antibiotic susceptibility profiles of these persistent isolates were different from those of the original isolates and these isolates could be new colonizers. In four patients who had no microbiological response after 72 hours of colistin treatment, the serum levels of colistin were measured by bioassay and the results showed that colistin levels were adequate at 4-8 times above the MIC of the organism. Therefore the same dose of colistin was continued for 7 days and all patients eventually had a microbiological response. We excluded patients with infections caused by A. baumannii or P. aeruginosa with other bacteria from our study, therefore the efficacy of colistin for treatment of mixed infections is unknown.
Nephrotoxicity is an important side effect of colistin. In our study, nephrotoxicity was found in 30.8% of the patients receiving colistin; this is comparable to the results found in a previous report. 15 Some patients in the colistin group who developed nephrotoxicity also had other contributing factors. Nephrotoxicity in these patients was mild and reversible without requiring renal replacement therapy. Some patients had improvement in their renal function after colistin treatment, which implies that the worsening of renal function was probably due to a severe infection or other conditions. The incidence of nephrotoxicity of the patients in the non-colistin group was significantly more than that in the colistin group. This observation might be due to uncontrolled infections and the side effects of medications including antibiotics given to the patients. No neurotoxicity or drug reaction was observed in the patients in our series.
Although the ability of Gram-negative bacteria to develop resistance to colistin is rare, such Gram-negative bacteria can develop resistance to colistin through mutation or adaptation mechanisms. 13, 16 We therefore recommend that colistin, as the only currently available drug for the treatment of MDR Gram-negative bacteria in Thailand, should be reserved for treatment of infections caused by multidrug-resistant Gram-negative bacteria that are only susceptible to colistin.
In summary, we found that colistin appears to be safe and effective for treatment of infections caused by multidrugresistant P. aeruginosa and A. baumannii in Thai adult patients. Treatment with colistin decreases patient mortality and is cost-effective.
